Northern Africa and Western Asia vs Tajikistan: Proportion of the target population who received
Northern Africa and Western Asia
78.0%
in 2024
Tajikistan
97.0%
in 2024
Northern Africa and Western Asia rank
19th
Tajikistan rank
21st
Proportion of the target population who received over time
- Northern Africa and Western Asia
- Tajikistan
How they compare
Tajikistan currently reports 97.0% against 78.0% in Northern Africa and Western Asia, a difference of 19.0%.
That makes Tajikistan's figure about 1.2 times Northern Africa and Western Asia's.
Across all 25 years both countries report, Tajikistan has been ahead every year.
Northern Africa and Western Asia ranks 19th and Tajikistan ranks 21st of 37 groups.
Tajikistan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Northern Africa and Western Asia | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 63.3% | 87.4% | 24.1% | Tajikistan |
| 2010s | 77.5% | 96.6% | 19.1% | Tajikistan |
| 2020s | 80.0% | 96.6% | 16.6% | Tajikistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received, Northern Africa and Western Asia or Tajikistan?
- Tajikistan, at 97.0% against 78.0% in Northern Africa and Western Asia as of 2024.
- What is the difference in proportion of the target population who received between Northern Africa and Western Asia and Tajikistan?
- 19.0%, with Tajikistan ahead.
- How many years of comparable data are there for Northern Africa and Western Asia and Tajikistan?
- 25 years are reported by both, from 2000 to 2024.
- How do Northern Africa and Western Asia and Tajikistan rank globally for proportion of the target population who received?
- Northern Africa and Western Asia ranks 19th and Tajikistan ranks 21st of 37 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received measles-containing-vaccine second-dose (MCV2) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.